450 results about "AIDS diagnosis" patented technology

The invention relates to a multichannel micro-fluidic chip specially used for AIDS diagnosis and comprising quasi-one-dimensional sensitive electrodes, belonging to the field of test. One of the hopes in the progress of medical techniques is to quickly diagnose AIDS at low cost. The invention provides a micro-fluidic chip that uses a plurality of AIDS characteristic antibodies to simultaneously detect and quickly diagnose AIDS. The chip is provided with three micro liquid storage tanks. The key points of the proposal lie in that the inner of the chip contains capillary channels of parallel structure, the parallel structure contains four micro-channels mutually connected in parallel, four working electrodes of bead string structure in total are respectively arranged in the four micro-channels, the substances on the superficial coats of the four working electrodes of bead string structure are respectively four antibody substances, namely, AIDS antibodies p24, gp41, gp120 and gp36. The application of the chip is conducive to increasing the diagnosis efficiency of AIDS as shown by the structural characteristics.

A computer-based detection method employable with a sleeping subject for aiding in the differential-character diagnosis and treatments of apneic events includes gathering heart-sound data, including S1 data and S2 data. A combined time-frequency-intensity (TFI) analysis, of the gathered data is performed, in a continuous manner, over a selected time period. Based on the performing and the performed TFI analysis, an output is produced which is indicative of the presence and character of any detected apneic event.

The invention discloses a kit for assisted diagnosis of tuberculosis, which comprises a specific antibody composition, wherein the specific antibody composition comprises the following five antibodies: (1) IFN-gamma antibody, (2) TNF-alpha antibody, (3) IL-2 antibody, (4) MIG antibody and (5) IP-10 antibody. The kit disclosed by the invention can distinguish a Mycobacterium tuberculosis infected person from a BCG vaccinee. Compared with the ELISPOT tuberculosis diagnosis method, the tuberculosis diagnosis kit based on multi-molecular marker detection has obviously enhanced sensitivity to active tuberculosis (from 72% to 89%), and the positive rate for normal healthy persons is obviously reduced (from 27% to 16%).

The invention belongs to the genetic engineering and tumour medicine fields and discloses an SNP marker related to primary hepatocellular carcinoma auxiliary diagnosis and an application of the SNP marker. The marker is a combination of rs7574865, rs1012068, rs17401966, rs2596542, rs455804, rs9272105, rs9275319 and rs9275572. The marker can be used for preparing a hepatic carcinoma auxiliary diagnosis kit.

The invention belongs to the technical field of immunologic diagnosis and particularly relates to a human immunodeficiency virus (HIV) antibody detection kit using a microparticle chemiluminiscence method and a preparation method of the kit. The kit is composed of magnetic microparticles for detecting an HIV antibody, a tracing conjugate for detecting the HIV antibody, a negative control, a I type positive control, a II type positive control and an analyzing buffering solution. The invention further discloses the preparation method of the detection kit, which adopts a particle chemiluminiscence immunoassay technology; compared with ELISA (Enzyme-Linked Immunosorbent Assay), the technology has higher sensitivity and specificity and is suitable for the clinical auxiliary diagnosis of HIV.

The invention relates to the field of diagnosis and treatment of liver cirrhosis and liver fibrosis, in particular to application of Golgi protein 73(GP73) and matter for detecting the concentration of the Golgi protein 73(GP73) in preparation of products for screening or auxiliarily diagnosing liver cirrhosis or liver fibrosis related diseases or products for auxiliarily judging prognosis of the diseases. It is proved that the Golgi protein 73(GP73) can serve as a novel liver cirrhosis marker, also has diagnosis value on liver cirrhosis caused by non-b hepatitis virus infection, and has no diagnosis value on primary liver cancer.

The invention discloses a test kit of auxiliary diagnosis of non-small cell lung cancer patients. The test kit comprises a product used for detecting protein landmark isocitrate dehydrogenase 1(IDH1), a product used for detecting protein landmark carbonic anhydrase 125 (CA125), a product used for detecting protein landmark CYFRA21-1 and a carrier on which a functional expression p=1/(1+(20.186*0.406<x1>*0.923<x2>*0.656<x3>)<-1>) is recorded, wherein x1 represents the concentration of IDH1, x2 represents the concentration of CA125, and x3 represents the concentration of CYFRA21-1. The test kit is adopted and the non-small cell lung cancer patients are diagnosed in an auxiliary mode according to corresponding diagnosis standards, the test kit has the advantages of being high in sensitivity and strong in specificity, reliability of the diagnosis is far higher than that of diagnosis which is carried out with each single protein landmark, and the test kit has great value and application prospects for diagnosis and treatment of non-small cell lung cancer.

The invention discloses a nasopharyngeal carcinoma auxiliary diagnosis model construction and auxiliary diagnosis method and system, and relates to the technical field of medical data processing. Thenasopharyngeal carcinoma auxiliary diagnosis model construction method comprises the steps: sample acquiring: acquiring a nasal endoscope image, wherein the nasal endoscope image comprises a nasopharyngeal carcinoma group and a non-nasopharyngeal carcinoma group; preprocessing: preprocessing the nasal endoscope image; and model training: inputting the preprocessed nasal endoscope image into a convolutional neural network, and training the convolutional neural network to obtain a nasopharyngeal carcinoma auxiliary diagnosis model. According to the invention, the nasopharyngeal endoscope image can be analyzed, and the predicted illness probability is output in real time to assist a doctor in nasopharyngeal carcinoma diagnosis, so that the accuracy of nasopharyngeal carcinoma diagnosis can beeffectively improved, and the biopsy detection rate is increased so as to achieve the purposes of early screening, early diagnosis and early treatment of nasopharyngeal carcinoma and improvement of treatment effect and prognosis of patients.

The invention discloses a kit for diagnosing primary hepatoma, preparation method and application thereof. The kit can quickly and accurately carry out the clusterin detection so as to carry out quickauxiliary diagnosis on the primary hepatoma of each period; and the kit especially has an important clinical application value for distinguishing hepatocirrhosis and early liver cancer. The kit comprises an enzyme-linked immunological diagnosis system established on the basis of a double-antibody sandwich principle. The kit has high sensitivity, strong specificity, simple operation, stable reagent, good repeatability, easy popularization and application and extensive market prospect.

The invention discloses a pancreatic ductal adenocarcinoma marker and a screening method thereof, which belongs to the field of clinical test and diagnosis. In view of the problem that the detection sensitivity and the detection specificity of the existing pancreatic ductal adenocarcinoma diagnosis marker are poor, serum of an early patient of early stage pancreatic duct adenocarcinoma is subjected to a trace metabolomics analysis by the high-performance liquid chromatography-tandem mass spectrometry technology, and different metabolites between normal human and the early stage pancreatic ductal adenocarcinoma patients are found. The different metabolites between normal human and pancreatic ductal adenocarcinoma patients are further analyzed by this technique to find the specific differentmetabolites C10:1 acyl carnitine and lysophosphatidyl choline LysoPC (14:0) of pancreatic ductal adenocarcinoma patients caused by cancer, i.e., the diagnostic molecules of the pancreatic ductal adenocarcinoma. According to the pancreatic ductal adenocarcinoma marker and the screening method thereof, the method can assist CA19-9 in diagnosing pancreatic duct adenocarcinoma patients, and can improve the diagnosis rate for the CA19-9 negative patients by 85%. The method is suitable for the screening of tumor markers.

The invention discloses an ectopic pregnancy and pregnant days colloid gold detection agent and manufacturing method thereof used for the problem of fast detection for pregnancy, comprising a piece of detecting test paper and urine sample treatment solution; wherein, the detecting test paper consists of a base plate, a cellulose nitrate membrane, a gold label anti-Beta HCG monoclone antibody layer, an Alpha-HCG monoclone antibody line, a sheep anti-rat polyclonal antibody line, an absorbing pad and a sample pad; the matching composition of the urine sample treatment solution is that: 12.5 to 18.0 portions of disodium hydrogen phosphate dodecahydrate, 1.2 to 1.7 portions of sodium dihydrogen phosphate dihydrate, 40.0 to 48.0 portions of sodium chloride and 4600 to 5300 portions of distilled water; the ectopic pregnancy and pregnant days colloid gold detection agent and manufacturing method of the invention are characterized by fast and simple detection, the operation of blood-drawing detection for 2 to 6 hours can be replaced by 2 to 3 minutes with time-saving, manual-saving and cost-saving; besides, the ectopic pregnancy and pregnant days colloid gold detection agent and manufacturing method thereof have the advantages of detecting ectopic pregnancy and pregnant days in a semiquantitative way, etc., and can be used for external detection of the pregnant condition and artificial abortion and assisted diagnosis.

The invention discloses a serum/plasma miRNA marker related to assisted diagnosis of intrahepatic cholestasis of pregnancy and an application of the serum/plasma miRNA marker. The serum/plasma miRNA marker related to ICP assisted diagnosis consists of miR-371a-5p, miR-6865-5p and miR-1182. The invention also discloses a primer of the serum/plasma miRNA marker and an application of the primer in preparing an ICP assisted diagnosis kit. The inventor, by separating and researching ICP cases of first pregnancy and singleton pregnancy and by comparing miRNAs in serum/plasma between the cases and healthy pregnant women matched in age, finds out a group of high-specificity and high-sensitivity miRNAs highly related to ICP attack; and an ICP assisted diagnosis kit convenient for clinical application is researched out, so that laboratory support is provided for screening and diagnosis & treatment of the ICP.

The invention discloses applications of miR-455-3p in the diagnosis, treatment, and prognosis of esophageal squamous cancer. The inventor finds that the obviously low survival rate of ESCC patients is related with the high expression of miR-455-3p in ESCC patients. The in-vitro and in-vivo experiment results show that miR-455-3p is capable of promoting the malignant progression of ESCC, by inhibiting the expression of miR-455-3p, the ESCC stem cell characteristics can be inhibited, and the sensitivity of ESCC stem cells to chemotherapy drugs is enhanced; so an expression inhibitor of miR-455-3p can inhibit the tumor stem cells, and is capable of inhibiting the tumor stem cell characteristics and enhancing the sensitivity of the cancer stem cells to chemotherapy drugs. The invention finds the expression of miR-455-3p in cancer patients for the first time, and the expression can be used as auxiliary diagnosis and/or prognosis of ESCC. The invention provides a novel diagnosis method, a novel treatment method, and a pharmaceutical drug screening platform for tumor diseases.

The invention relates to the technical field of biological and medical detection, in particular relates to a time-resolved fluorescence immunodetection kit capable of simultaneously and comprehensively detecting four indexes of HE4, CA125, CEA and TPS in ovarian cancer tumor markers in a same reaction system, and also relates to application of the kit to comprehensive detection of the four indexes of HE4, CA125, CEA and TPS in the ovarian cancer tumor markers. The kit comprises a porous plate coated with a first monoclonal antibody mixture which resists the HE4, CA125, CEA and TPS respectively, an Sm<3+> labeled anti-HE4, Eu<3+> labeled anti-CA125, Tb<3+> labeled anti-CEA and Dy<3+> labeled anti-TPS second monoclonal antibody mixture, an analytical buffer solution, a common fluorescence enhancer, a cleaning solution and a quality control material. The kit provided according to the invention can be used for clinical auxiliary diagnosis, observation of curative effect and prognosis of ovarian cancer, has significance for treatment and prevention of the ovarian cancer tumor, and can be used for detecting the four tumor markers simultaneously, thus simplifying the detection steps and improving the specificity and sensitivity of comprehensive analysis of detected data.

The invention discloses an application method of a machine learning classification model in adolescent autism auxiliary diagnosis. The method is characterized by being implemented according to the following mode. The method comprises the steps of 1, establishing a model training method; 2, constructing a model evaluation index; 3, performing characteristic engineering of the autism auxiliary diagnosis system; 4, performing data dimension reduction processing; 5, carrying out feature selection; and 6, carrying out model training and result analysis. According to the invention, a machine learning method is introduced into the field of autism research; the high efficiency and the reliability brought by the method are greatly helpful to the auxiliary diagnosis of autism. The application fieldof the invention can be embodied in: (1) disease diagnosis and treatment, (2) smoking addiction, network addiction and network game addiction, (3) cognition and other health fields, and the like.

The invention relates to the field of biomedicine, and particularly to screening and application of a feces gene marker based on high-flux metagenome sequencing analysis. According to the method, through extracting feces DNA for performing macro genome sequencing and ROC curve analysis by means of a shotgun method, the gene marker is screened, and furthermore the gene marker is verified through fluorescent real-time quantified PCR for obtaining consistency. According to the method, metagenome high-flux shotgun sequencing technical measurement is firstly performed in feces of Chinese PD patients, and a screening method for the feces gene marker is established; various different genes in the feces of the PD patient are found; 25 feces gene markers are screened as PD diagnosis markers for auxiliary diagnosis of the PD patient; and the method has important academic meaning and application prospect for enriching and further understanding the pathological mechanism of PD.

The invention discloses application of a product for detecting ceramide in preparation of a kit. The application of the kit is at least one of the following (a1)-(a3): (a1) screening or assisting in diagnosing heart failure patients; (a2) evaluating or assisting in evaluating the prognosis risk of heart failure patients; and (a3) evaluating or assisting in evaluating the adverse event risk of heart failure patients. Research results show that the ratio of plasma ceramide cer (d18: 1/16: 0) to cer (d18: 1/24: 0) is an important predictive factor for the occurrence of adverse events of heart failure in patients with heart failure at the final stage, and is independent of currently used lipid markers, which facilitates the identification of high risk patients requiring more positive therapeutic interventions.

The invention discloses an application of CD4+CD70+T cell subset in preparing reagent for auxiliary diagnosis of very severe aplastic anemia. According to the invention, the inventor finds for the first time that the proportion of CD4+CD70+T cell in the peripheral blood of AA patients is obviously reduced in A patients, especially, is most obvious in VSAA, which can be used as one of related testindices for auxiliary diagnosis of laboratory immunization of VSAA patients, and meanwhile, provides important reference data for selection of treatment strategy for VSAA patients clinically.

The invention discloses a marker joint detection model for diagnosis of the lung cancer. According to the invention, a carcinoembryonic antigen, a cancer antigen 125, an annexin A1 antibody and an alpha-enolase antibody are used as markers and are applied to preparation of a product for the diagnosis or assisted diagnosis of the lung cancer. According to the invention, the good optimization modelbeing optimal diagnosis combination of four kinds of biomarkers (the CEA, CA125, annexin A1 antibody and and alpha-enolase antibody) is established, wherein the e good optimization model has the better diagnosis capability superior to the single traditional marker diagnosis. The marker joint detection model as a novel method for lung cancer diagnosis has advantages of high sensitivity and specificity and has the important significance in accurate diagnosis of the lung cancer.

The invention relates to a cancer diagnosis technology, in particular to application of serum IL-6 in the preparation of a primary hepatocellular carcinoma diagnostic reagent kit. The reagent kit can quickly and accurately detect the IL-6, thereby performing quick assistant diagnosis to primary hepatocellular carcinoma at each stage (particularly at early stage) and having important clinical application value. The invention comprises the establishment of an enzyme-linked immune diagnosis system based on a double antibody sandwich principle. The serum does not need to be diluted, so the sensitivity is greatly improved. The application has the advantages that the detection reagent kit has simple operation, steady reagent, good repetitiveness, strong specificity, and high sensitivity, is easy to promote and apply within large range, and has broad market prospect.

The invention belongs to the field of molecular biological detection, particularly belongs to the field of liver cancer detection, provides an application of a reagent in the preparation of a kit forauxiliary diagnosis of liver cancer, and also provides the reagent for auxiliary diagnosis of the liver cancer, and the kit containing the reagent. The reagent can be used for diagnosing liver cancerat least with the sensitivity of 82.35% and the specificity of 100%, and the area under a curve is 0.8720 or above.

Methods for diagnosing or assisting in the diagnosis of iron-related pathologies are provided. The methods are based on the correlation of the degree of iron-specific hypercoagulability with clinical disease. One embodiment provides a method for diagnosing or assisting in diagnosing a subject having or suspected of having an iron-related pathology by analyzing a blood sample obtained from the subject to obtain viscoelastic parameters of the blood sample as the blood sample coagulates. A variation in the viscoelastic parameters of the blood sample relative to a blood sample from a healthy subject indicates the subject has or will likely develop an iron-related pathology. Subjects having an iron-related pathology have viscoelastic parameters that are indicative of enhanced coagulation and/or diminished fibrinolysis compared to the viscoelastic parameters of the blood sample from the healthy subject.

The invention relates to a diagnostic marker for the colorectal cancer and a detection product for the colorectal cancer and an application thereof. The colorectal cancer diagnostic marker comprises aplurality of kinds of secreted protein including one or more of S100A9 protein, tenascin-c protein and CEA protein. The diagnostic marker has characteristics of high sensitivity and strong specificity. The area under the roc curve of the diagnostic model is 0.902. The confidence level of the diagnosis result is much higher than that of the diagnosis result using a single protein marker. The diagnostic marker has the important significance in colorectal cancer diagnosis and treatment. Besides, the detection product of the colorectal cancer includes the colorectal cancer diagnostic marker. In addition, the invention also puts forward application of the colorectal cancer diagnostic marker in preparation of a product for the auxiliary diagnosis of the colorectal cancer.

The present invention relates to applications of Mycobacterium tuberculosis antigen protein Rv0446c and a T-cell epitope peptide thereof in preparation of tuberculosis detection reagents, vaccines and medicines, wherein the amino acid sequences of the antigen protein Rv0446c and the T-cell epitope peptide thereof are respectively represented by SEQ ID NO:1-5. According to the present invention, the Mycobacterium tuberculosis antigen protein Rv0446c and the T-cell epitope peptide thereof are used as the stimulants for the specific T cell and B cell immune response caused by Mycobacterium tuberculosis infection, and the false positive caused by the impure antigen can be reduced compared with the use of the complete antigen in the prior art; and the detection reagents prepared from the antigen protein Rv0446c and the T-cell epitope peptide thereof can be widely used for assisted diagnosis of tuberculosis, epidemiological surveillance and other related fields, and the tuberculosis vaccines and the anti-tuberculosis drugs prepared from the antigen protein Rv0446c and the T-cell epitope peptide thereof can be used for prevention and treatment of tuberculosis.